Gilead Sciences, Inc. has endured some setbacks in bringing its first-in-class capsid inhibitor lenacapavir to the finish line, but with a marketing authorization from the European Medicines Agency on 19 August the biopharma may be on the way to realizing its broad ambitions for the long-acting oral or injectable drug. Branded as Sunlenca, the drug’s initial approval is as part of combination therapy in multi-drug-resistant HIV patients who cannot achieve viral suppression with another regimen.
[Sidebar#SC143338]
